These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 15173071

  • 1. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.
    Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, Langmuir P, Wheeler C, Stone A, Leadbetter J, Ryan AJ, Blakey DC, Waterton JC.
    Clin Cancer Res; 2004 Jun 01; 10(11):3650-7. PubMed ID: 15173071
    [Abstract] [Full Text] [Related]

  • 2. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
    Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, Hill SA.
    Cancer Res; 2002 Dec 15; 62(24):7247-53. PubMed ID: 12499266
    [Abstract] [Full Text] [Related]

  • 3. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.
    Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS.
    J Clin Oncol; 2005 Aug 20; 23(24):5464-73. PubMed ID: 16027440
    [Abstract] [Full Text] [Related]

  • 4. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
    Goto H, Yano S, Matsumori Y, Ogawa H, Blakey DC, Sone S.
    Clin Cancer Res; 2004 Nov 15; 10(22):7671-6. PubMed ID: 15570000
    [Abstract] [Full Text] [Related]

  • 5. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.
    Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ.
    Clin Cancer Res; 2002 Jun 15; 8(6):1974-83. PubMed ID: 12060643
    [Abstract] [Full Text] [Related]

  • 6. Detecting vascular-targeting effects of the hypoxic cytotoxin tirapazamine in tumor xenografts using magnetic resonance imaging.
    Bains LJ, Baker JH, Kyle AH, Minchinton AI, Reinsberg SA.
    Int J Radiat Oncol Biol Phys; 2009 Jul 01; 74(3):957-65. PubMed ID: 19480975
    [Abstract] [Full Text] [Related]

  • 7. Segmentation of dynamic contrast enhanced magnetic resonance imaging data.
    Nielsen T, Mouridsen K, Maxwell RJ, Stødkilde-Jørgensen H, Østergaard L, Horsman MR.
    Acta Oncol; 2008 Jul 01; 47(7):1265-70. PubMed ID: 18661437
    [Abstract] [Full Text] [Related]

  • 8. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging.
    Robinson SP, McIntyre DJ, Checkley D, Tessier JJ, Howe FA, Griffiths JR, Ashton SE, Ryan AJ, Blakey DC, Waterton JC.
    Br J Cancer; 2003 May 19; 88(10):1592-7. PubMed ID: 12771928
    [Abstract] [Full Text] [Related]

  • 9. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
    Lee L, Sharma S, Morgan B, Allegrini P, Schnell C, Brueggen J, Cozens R, Horsfield M, Guenther C, Steward WP, Drevs J, Lebwohl D, Wood J, McSheehy PM.
    Cancer Chemother Pharmacol; 2006 Jun 19; 57(6):761-71. PubMed ID: 16172907
    [Abstract] [Full Text] [Related]

  • 10. Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers.
    Wang H, Cona MM, Chen F, Yu J, Feng Y, Li J, Keyzer FD, Marchal G, Ni Y.
    Anticancer Drugs; 2012 Jan 19; 23(1):12-21. PubMed ID: 21857503
    [Abstract] [Full Text] [Related]

  • 11. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice.
    Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC, Sone S.
    Cancer Res; 2002 Jul 01; 62(13):3711-5. PubMed ID: 12097279
    [Abstract] [Full Text] [Related]

  • 12. Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors.
    Skliarenko JV, Lunt SJ, Gordon ML, Vitkin A, Milosevic M, Hill RP.
    Cancer Res; 2006 Feb 15; 66(4):2074-80. PubMed ID: 16489007
    [Abstract] [Full Text] [Related]

  • 13. Antitumor effect of the vascular-disrupting agent ZD6126 in a murine renal cell carcinoma model.
    Medinger M, Esser N, Soltau J, Lehmann KM, Konerding MA, Wolloscheck T, Ryan AJ, Drevs J.
    Int J Oncol; 2011 Feb 15; 38(2):455-64. PubMed ID: 21152862
    [Abstract] [Full Text] [Related]

  • 14. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent.
    Micheletti G, Poli M, Borsotti P, Martinelli M, Imberti B, Taraboletti G, Giavazzi R.
    Cancer Res; 2003 Apr 01; 63(7):1534-7. PubMed ID: 12670901
    [Abstract] [Full Text] [Related]

  • 15. Combination of the vascular targeting agent ZD6126 with boron neutron capture therapy.
    Masunaga S, Sakurai Y, Suzuki M, Nagata K, Maruhashi A, Kinash Y, Ono K.
    Int J Radiat Oncol Biol Phys; 2004 Nov 01; 60(3):920-7. PubMed ID: 15465210
    [Abstract] [Full Text] [Related]

  • 16. Correlations between dynamic contrast-enhanced magnetic resonance imaging-derived measures of tumor microvasculature and interstitial fluid pressure in patients with cervical cancer.
    Haider MA, Sitartchouk I, Roberts TP, Fyles A, Hashmi AT, Milosevic M.
    J Magn Reson Imaging; 2007 Jan 01; 25(1):153-9. PubMed ID: 17173303
    [Abstract] [Full Text] [Related]

  • 17. Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126.
    Cullis ER, Kalber TL, Ashton SE, Cartwright JE, Griffiths JR, Ryan AJ, Robinson SP.
    Microvasc Res; 2006 Mar 01; 71(2):76-84. PubMed ID: 16530791
    [Abstract] [Full Text] [Related]

  • 18. Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure.
    Ferretti S, Allegrini PR, O'Reilly T, Schnell C, Stumm M, Wartmann M, Wood J, McSheehy PM.
    Clin Cancer Res; 2005 Nov 01; 11(21):7773-84. PubMed ID: 16278399
    [Abstract] [Full Text] [Related]

  • 19. Diffusion-weighted and macromolecular contrast enhanced MRI of tumor response to antivascular therapy with ZD6126.
    Vogel-Claussen J, Gimi B, Artemov D, Bhujwalla ZM.
    Cancer Biol Ther; 2007 Sep 01; 6(9):1469-75. PubMed ID: 17881899
    [Abstract] [Full Text] [Related]

  • 20. The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS.
    Breidahl T, Nielsen FU, Stødkilde-Jørgensen H, Maxwell RJ, Horsman MR.
    Acta Oncol; 2006 Sep 01; 45(3):306-16. PubMed ID: 16644574
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.